Summary:
The optimal approach to obtain an adequate graft for transplantation in patients with poor peripheral blood stem cell (PBSC) mobilization remains unclear. We retrospectively assessed the impact of different strategies of second-line stem cell harvest on the transplantation outcome of patients who failed PBSC mobilization in our institution. Such patients were distributed into three groups: those who proceeded to steady-state bone marrow (BM) collection (group A, n=34); those who underwent second PBSC mobilization (group B, n=41); those in whom no further harvesting was carried out (group C, n=30). PBSC harvest yielded significantly more CD34+ cells than BM collection. Autologous transplantation was performed in 30, 23 and 11 patients from groups A, B and C, respectively. Engraftment data and transplantation outcome did not differ significantly between groups A and C. By contrast, group B patients had a faster neutrophil recovery, required less platelet transfusions and experienced less transplant-related morbidity, as reflected by lower antibiotics needs and shorter hospital stays. In conclusion, remobilization of PBSC constitutes an effective approach to ensure a rapid hematopoietic engraftment and a safe transplantation procedure for poor mobilizers, whereas unprimed BM harvest does not provide any clinical benefit in this setting.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
To LB, Haylock DN, Simmons PJ, Juttner CA . The biology and clinical uses of blood stem cells. Blood 1997; 89: 2233–2258.
Schmitz N, Linch DC, Dreger P et al. Randomized trial of filgrastim mobilized peripheral blood progenitor cell transplant versus autologous bone marrow transplantation in lymphoma patients. Lancet 1996; 347: 353–357.
Damiani D, Fanin R, Silvestri F et al. Randomized trial of autologous filgrastim-primed bone marrow transplantation versus filgrastim-mobilized peripheral stem cell transplantation with lymphoma patients. Blood 1997; 90: 36–42.
Weaver CH, Potz J, Redmond J et al. Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34+ cell content. Bone Marrow Transplant 1997; 19: 1103–1110.
Watts MJ, Ings SJ, Flynn M et al. Remobilization of patients who fail to achieve minimal progenitor thresholds at the first attempt is clinically worthwhile. Br J Haematol 2000; 111: 287–291.
Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547–2555.
Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961–3969.
Dreger P, Kloss M, Petersen B et al. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995; 86: 3970–3978.
Tarella C, Di Nicola M, Caracciolo D . High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization. Bone Marrow Transplant 2002; 30: 725–732.
Koumakis G, Vassiolmanolakis M, Hatzichristou H et al. Predictive factors affecting mobilization and peripheral blood stem cell collection using single apheresis for rescuing patients after high-dose chemotherapy in various malignancies. Bone Marrow Transplant 1996; 18: 1065–1072.
Brugger W, Bross K, Frisch J et al. Mobilization of peripheral blood progenitors by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide and cisplatin. Blood 1992; 79: 1193–1200.
Haas R, Mohle R, Fruehauf S et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787–3794.
Zimmerman TM, Michelson GC, Mick R et al. Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G-CSF in patients with lymphoma. J Clin Apheresis 1999; 14: 31–34.
Kessinger A, Sharp JG . The whys and hows of hematopoietic progenitor and stem cell mobilization. Bone Marrow Transplant 2003; 31: 319–329.
Fraipont V, Sautois B, Baudoux E et al. Successful mobilization of peripheral blood HPCs with G-CSF alone in patients failing to achieve sufficient numbers of CD34+ cells and/or CFU-GM with chemotherapy and G-CSF. Transfusion 2000; 40: 339–347.
Carlo-Stella C, Di Nicola M, Milani R et al. Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers. Blood 2004; 103: 3287–3295.
Weaver CH, Tauer K, Zhen B et al. Second attempts at mobilization of peripheral blood stem cells in patients with initial low CD34+ cell yields. J Hematother 1998; 7: 241–249.
Gazitt Y, Freytes CO, Callander N et al. Successful PBSC mobilization with high-dose G-CSF for patients failing a first round of mobilization. J Hematother 1999; 8: 173–183.
Lefrère F, Lévy V, Makke J et al. Successful peripheral blood stem cell harvesting with granulocyte colony-stimulating factor alone after previous mobilization failure. Haematologica 2004; 89: 1532–1533 [letter].
Bashey A, Corringham S, Gilpin E et al. Simultaneous administration of G-CSF and GM-CSF for re-mobilization in patients with inadequate initial progenitor cell collections for autologous transplantation. Cytotherapy 2000; 2: 195–200.
Watts MJ, Sullivan AM, Leverett D et al. Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem cell mobilization. J Clin Oncol 1998; 16: 1554–1560.
Rick O, Beyer J, Kingreen D et al. Successful autologous bone marrow rescue in patients who failed peripheral blood stem cell mobilization. Ann Hematol 2000; 79: 681–686.
Sugrue MW, Williams K, Pollock BH et al. Characterization and outcome of ‘hard to mobilize’ lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2000; 39: 509–519.
Scott MA, Ager S, Jestice HK et al. Failure to mobilize and harvest PBPC does not necessarily preclude the use of high-dose therapy and autologous stem-cell rescue. Bone Marrow Transplant 1995; 15: 487–488 [letter].
Lemoli RM, de Vivo A, Damiani D et al. Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization. Blood 2003; 102: 1595–1600.
Elfenbein GJ, Sackstein R . Primed marrow for autologous and allogeneic transplantation: a review comparing primed marrow to mobilized blood and steady-state marrow. Exp Hematol 2004; 32: 327–339.
Stockerl-Goldstein KE, Reddy SA, Horning SJ et al. Favorable treatment outcome in non-Hodgkin's lymphoma patients with poor mobilization of peripheral blood progenitor cells. Biol Blood Marrow Transplant 2000; 6: 506–512.
Arbona C, Prosper F, Benet I et al. Comparison between once a day vs twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC) in normal donors for allogeneic PBPC transplantation. Bone Marrow Transplant 1998; 22: 39–45.
Moncada V, Bolan C, Yau YY, Leitman SF . Analysis of PBPC cell yields during large-volume leukapheresis of subjects with a poor mobilization response to filgrastim. Transfusion 2003; 43: 495–501.
Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C . Therapeutic relevance of CD34+ cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18: 1360–1377.
Stewart DA, Guo D, Luider J et al. The CD34+90+ cell dose does not predict early engraftment of autologous blood stem cells as well as the total CD34+ cell dose. Bone Marrow Transplant 2000; 25: 435–440.
Carral A, de la Rubia J, Martin G et al. Factors influencing hematopoietic recovery after autologous blood stem cell transplantation in patients with acute myeloblastic leukemia and with non-myeloid malignancies. Bone Marrow Transplant 2002; 29: 825–832.
Meisenberg B, Brhem T, Schmekel A et al. A combination of low-dose cyclophosphamide and colony stimulating factors is more cost-effective than granulocyte-colony stimulating factors alone in mobilizing peripheral blood stem and progenitor cells. Transfusion 1998; 38: 209–215.
Narayanasami U, Kanteli R, Morelli J et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001; 98: 2059–2064.
Meldgaard L, Jensen L, Gaarsdal E et al. A comparative study of sequential priming and mobilisation of progenitor cells with rhG-CSF alone and high-dose cyclophosphamide plus rhG-CSF. Bone Marrow Transplant 2000; 26: 717–722.
Milone G, Leotta S, Indelicato F et al. G-CSF alone vs cyclophosphamide plus G-CSF in PBPC mobilization of patients with lymphoma: results depend on degree of previous pre-treatment. Bone Marrow Transplant 2003; 31: 747–754.
Acknowledgements
We thank all nurses at the departments for the excellent and skillful care to the patients.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Goterris, R., Hernández-Boluda, J., Teruel, A. et al. Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobilizers. Bone Marrow Transplant 36, 847–853 (2005). https://doi.org/10.1038/sj.bmt.1705147
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705147
Keywords
This article is cited by
-
LECT2 drives haematopoietic stem cell expansion and mobilization via regulating the macrophages and osteolineage cells
Nature Communications (2016)
-
Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization
Bone Marrow Transplantation (2015)
-
Intermediate-dose Ara-C plus G-CSF for stem cell mobilization in patients with lymphoid malignancies, including predicted poor mobilizers
Bone Marrow Transplantation (2013)
-
Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4
Leukemia (2012)
-
Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA
Bone Marrow Transplantation (2012)